S&P ASX All Technology

US Dollar vs AUD

Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

Get Started

FUSN Fusion Pharmaceuticals Inc

21.2001

-0.2599 (-1.21%)

18 May 2024 - Closed

Delayed by 15 minutes

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Article too big to display. Click here to view on the SEC website

Fusion Pharmaceuticals (NASDAQ:FUSN)
Historical Stock Chart
From Apr 2024 to May 2024

Click Here for more Fusion Pharmaceuticals Charts.

Fusion Pharmaceuticals (NASDAQ:FUSN)
Historical Stock Chart
From May 2023 to May 2024

Click Here for more Fusion Pharmaceuticals Charts.

Fusion Pharmaceuticals Inc News

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Saturday 11 May 2024 (1 week ago) • Edgar (US Regulatory)

Form 8-K - Current report
Friday 10 May 2024 (1 week ago) • Edgar (US Regulatory)

Fusion Pharmaceuticals Announces First Patient Dosed in the Phase 2 Portion of the AlphaBreak Trial Evaluating FPI-2265 in Metastatic Castration-Resistant Prostate Cancer
Friday 10 May 2024 (1 week ago) • PR Newswire (Canada)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Tuesday 7 May 2024 (2 weeks ago) • Edgar (US Regulatory)

Form 8-K - Current report
Tuesday 7 May 2024 (2 weeks ago) • Edgar (US Regulatory)

Fusion Pharmaceuticals Reports First Quarter 2024 Financial Results and Announces Clinical Program Updates
Tuesday 7 May 2024 (2 weeks ago) • PR Newswire (US)

Kuehn Law Encourages HCP, IP, SLCA, and FUSN Investors to Contact Law Firm
Saturday 27 April 2024 (3 weeks ago) • PR Newswire (US)

Fusion Pharmaceuticals Mails Circular for Special Meeting of Shareholders and Announces Receipt of Interim Order
Friday 26 April 2024 (3 weeks ago) • PR Newswire (US)

Fusion Pharmaceuticals Announces Presentation of Interim Data from the Phase 2 TATCIST Clinical Trial Evaluating FPI-2265 at the AACR Annual Meeting 2024
Wednesday 10 April 2024 (1 month ago) • PR Newswire (Canada)

Kuehn Law Encourages DRQ, EVBG, FREE, and FUSN Investors to Contact Law Firm
Thursday 21 March 2024 (2 months ago) • PR Newswire (US)

Fusion Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Announces Clinical Program Updates
Thursday 21 March 2024 (2 months ago) • PR Newswire (US)

Fusion Pharmaceuticals to be Acquired by AstraZeneca, Accelerating Development of Next-Generation Radioconjugates to Treat Cancer
Tuesday 19 March 2024 (2 months ago) • PR Newswire (US)

More Fusion Pharmaceuticals Inc News Articles

Euronext S ING 070322 GR...

Telenor ASA (QX)

Aureus Nummus Gold

Capitan Silver (QB)

IXII TM31 EO CB 1D SF

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions